drug
Celebrex
Marketedupdated 3mo agoby Greenstone LLC
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval34 co-mentions · 17 sources
- drugElyxyb25 co-mentions · 19 sources
- drugcelecoxib SR25 co-mentions · 19 sources
- drugCELECOXIB25 co-mentions · 19 sources
- tagSmall Molecule17 co-mentions · 17 sources
- companyLupin Ltd8 co-mentions · 8 sources
- companyAlembic Pharmaceuticals Inc6 co-mentions · 1 sources
- tagRecall4 co-mentions · 2 sources
Small molecule drug with a maximum clinical stage of Approval (across all indications), with 17 approved and 80 investigational indications.
all catalysts(11)
approval · 11
Oct 29, 2014
approval
CELECOXIB — FDA approval
Celebrex
→
Jun 9, 2015
approval
CELECOXIB — FDA approval
Celebrex
→
Sep 16, 2016
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 9, 2019
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 9, 2019
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 9, 2019
approval
CELECOXIB — FDA approval
Celebrex
→
Mar 6, 2020
approval
CELECOXIB — FDA approval
Celebrex
→
Jan 5, 2022
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 15, 2025
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 15, 2025
approval
CELECOXIB — FDA approval
Celebrex
→
Oct 21, 2025
approval
CELECOXIB — FDA approval
Celebrex
→
Trials studying Celebrex
- phase2Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
- phase2Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer
- phase2Efficacy and Safety of TRD205 Tablets for Postoperative Analgesia in Unilateral Total Hip Arthroplasty (Phase IIb)
- phase3Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
- phase1A Phase Ib Study to Evaluate the Efficacy and Safety of HRS-2129 in Patients With Knee Osteoarthritis
- phase2Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer
- phase3Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimen
- phase1The Seven Trial: Exploiting the Unfolded Protein Response
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 19, 2030
~3.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (13)
- May 27, 2036formulationUS 10376527
- May 27, 2036formulationUS 10722456
- May 27, 2036formulationUS 10799517
- May 27, 2036formulationUS 9572819
- May 27, 2036formulationUS 9795620
- May 27, 2036formulationUS 9949990
- Jun 3, 2031formulationUS 88467444.8y
- Apr 19, 2030compositionUS 102386683.7y
- Apr 19, 2030compositionUS 102452763.7y
- Apr 19, 2030method-of-use (U-3244)US 105489093.7y
- Apr 19, 2030method-of-use (U-3244)US 114784883.7y
- Apr 19, 2030compositionUS 85981523.7y
- Apr 19, 2030compositionUS 90124403.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 30m ago
Found something off?
comments(0)
5-min edit window · permanent after that